Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP14 | P54578 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.49 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 12/20 | 0.46 |
| ▸ | HTR2A | P28223 | 10/20 | 0.46 |
| ▸ | DRD3 | P35462 | 10/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6217037 | 0.84 | MAOB (0.58) | MAOBSLC27A1DRD2HTR2ADRD3 | |
| SCHEMBL5567706 | 0.82 | KCNA3 (0.54) | KCNA3DRD2HTR2ADRD3CCR5 | |
| SCHEMBL7824714 | 0.81 | KCNA3 (0.48) | USP14MAOBKCNA3DRD2HTR2A | |
| SCHEMBL13857680 | 0.80 | KCNA3 (0.60) | USP14MAOBKCNA3DRD2DRD3 | |
| SCHEMBL7821912 | 0.79 | KCNA3 (0.46) | USP14MAOBKCNA3DRD2HTR2A | |
| SCHEMBL7827907 | 0.78 | KCNA3 (0.46) | USP14MAOBKCNA3DRD2HTR2A | |
| SCHEMBL13584122 | 0.76 | DRD2 (0.78) | DRD2HTR2ADRD3 | |
| SCHEMBL13584120 | 0.76 | DRD2 (0.78) | DRD2HTR2ADRD3 | |
| SCHEMBL21774707 | 0.73 | USP14 (0.63) | USP14KCNA3DRD2DRD3 | |
| SCHEMBL30886061 | 0.73 | KCNA3 (0.58) | USP14MAOBKCNA3DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6323217-B2 | CARDIOVASCULAR DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | disclosed |
| US-20010034352-A1 | Piperidine-4 sulphonamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034352-A1 | Piperidine-4 sulphonamide compounds | KDR, GLS, FLT1 | USP14 1266/4885MAOB 1601/4885KCNA3 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.